ClinicalTrials.gov
public full text
Public Domain
Open-label, Bioequivalence Study of Certolizumab Pegol 200 mg Solution Injected Either by a Prefilled Syringe (Reference) or by an E-Device (Test) in Healthy Subjects
This is a single center, open-label, Phase 1 bioequivalence (BE) study in healthy subjects designed to demonstrate the bioequivalence of a single dose of certolizumab pegol (CZP) 200mg when injected by means of a prefilled syringe (PFS, reference) or injected by means of a injection device (e-Device, test).
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- metronidazol 5 mg/ml 300 ml perfusion intravenosa#296872
- Bioequivalence Study of Tacrolimus 5 mg Capsule Under Fed Condition#1362861
- Cefprozil for Oral Suspension 250 mg/5 mL, Fasting#864785
- Pharmacokinetics Of Celecoxib Test Formulations#869636
- Bioequivalence Study Comparing Two Alprazolam 1 mg Tablets Under Fed Conditions#867162
Record · ID 1395300
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive